15 At that time, IP chemotherapy was considered an acceptable choice for patients with residual disease tumors of 1 cm or less after primary surgery. However, at the Consensus Conference on Ovarian ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially administered as an alternative treatment for patients not suitable for primary debulking surgery (PDS) because of unresectable ...

Patients with advanced ovarian cancer are known to have a 20–30% chance of survival, even when undergoing extensive chemotherapy. Xia Wu and co-workers now present evidence that the immune ...

See complete disclaimer in Appendix 1 and 2 (online only) for more. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with ...